What was announced

HUTCHMED said it will make a new and updated data presentation at ESMO Congress 2026, and the company is listed as Nasdaq/AIM: HCM; HKEX: 13.

The SAFFRON Global Phase III Study reported positive results on August 17, 2026 and was selected for a Presidential Symposium.

The SANOVO China Phase III Study reported positive results on August 31, 2026 and was selected for a Proffered Paper session.

Highlights

  • HUTCHMED said it will make a new and updated data presentation at ESMO Congress 2026.
  • SAFFRON Global Phase III Study reported positive results on August 17, 2026 and was selected for a Presidential Symposium.
  • SANOVO China Phase III Study reported positive results on August 31, 2026 and was selected for a Proffered Paper session.